Download PDF
Thromb Haemost 2004; 92(04): 838-845
DOI: 10.1160/TH04-04-0229
Wound Healing and Inflammation / Infaction
Schattauer GmbH

Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2

Beate Schneider
1   Institute of Medical Microbiology and Immunology
,
Maria Becker
1   Institute of Medical Microbiology and Immunology
,
Hans-Hermann Brackmann
2   Haemophilia Centre, Institute of Experimental Haematology and Transfusion Medicine; University of Bonn, Germany
,
Anna Maria Eis-Hübinger
1   Institute of Medical Microbiology and Immunology
› Author AffiliationsFinancial support: This work was carried out with financial support from the Commission of the European Community (Grant QLK2-CT-2001-00877).
Further Information

Publication History

Received 14 April 2004

Accepted after revision 13 July 2004

Publication Date:
06 December 2017 (online)

    Permissions and Reprints

Summary

Human parvovirus B19 (B19) DNA has frequently been detected in plasma-derived coagulation factor concentrates. Furthermore, transmission of B19 infection was observed, indicating presence of the infectious virus despite routine viral inactivation/removal procedures during the manufacturing process. Recently, human parvovirus DNA isolates, variant from B19, have been identified resulting in classification of B19 virus into three distinct genotypes, with all viruses previously classified as B19 belonging to genotype 1. So far, there is no information available on contamination of clotting factor concentrates with genotype 2. Therefore, we analysed 202 different factor concentrate lots for genotype 1 and 2 DNA by PCR. Analysis of one hundred eighty-one lots representing 13 different products, administered over the last three years, was compared to 21 lots (8 products) used until the early 1980s which had not been treated by viral inactivation procedures. Genotype 1 DNA was detected in 77/181 (42.5%) currently administered lots, and 17/21 (81%) previously used lots. The level of genotype 1 DNA contamination was similar in currently and previously administered concentrates. Genotype 2 DNA was found in 5/202 (2.5%) lots, all of which were co-contaminated with genotype 1 DNA. DNA sequence analysis showed that the PCR-double positive concentrates contained typical genotype 1 and genotype 2 DNA. Because genotype 2 appears to cause a similar spectrum of diseases as genotype 1, simultaneous detection of genotype 2 by nucleic acid amplification testing (NAT), now widely applied to plasma pools for genotype 1, would give an added level of safety to blood products.

Keywords

Human parvovirus - genotype 2 - coagulation factor concentrates
 

  • References

  • 1 Zakrzewska K, Azzi A, Patou G. et al. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br J Haematol 1992; 81: 407-12.
    CrossrefPubMedGoogle Scholar
  • 2 Lefrère JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated antihaemophilia concentrates. Lancet 1994; 343: 211-2.
    CrossrefPubMedGoogle Scholar
  • 3 Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93: 714-9.
    CrossrefPubMedGoogle Scholar
  • 4 Eis-Hübinger AM, Sasowski U, Brackmann HH. Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost 1999; 81: 476-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Schmidt I, Blümel J, Seitz H. et al. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001; 81: 228-35.
    CrossrefPubMedGoogle Scholar
  • 6 Bartolomei OCorsi, Azzi A, Morfini M. et al. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 1988; 25: 165-70.
    CrossrefPubMedGoogle Scholar
  • 7 Lyon DJ, Chapman CS, Martin C. et al. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1989; 01: 1085.
    PubMedGoogle Scholar
  • 8 Yee TT, Cohen BJ, Pasi KJ. et al. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93: 457-9.
    CrossrefPubMedGoogle Scholar
  • 9 Santagostino E, Mannucci PM, Gringeri A. et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization. Transfusion 1997; 37: 517-22.
    CrossrefPubMedGoogle Scholar
  • 10 Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204.
    CrossrefPubMedGoogle Scholar
  • 11 Hino M, Ishiko O, Honda KI. et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol 2000; 108: 194-5.
    CrossrefPubMedGoogle Scholar
  • 12 Blümel J, Schmidt I, Effenberger W. et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002; 42: 1473-81.
    CrossrefPubMedGoogle Scholar
  • 13 Nguyen QT, Sifer C, Schneider V. et al. Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemia. Lancet 1998; 352: 1524.
    PubMedGoogle Scholar
  • 14 Hokynar K, Söderlund-Venermo M, Pesonen M. et al. A new parvovirus genotype persistent in human skin. Virology 2002; 302: 224-8.
    CrossrefPubMedGoogle Scholar
  • 15 Servant A, Laperche S, Lallemand F. et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76: 9124-34.
    CrossrefPubMedGoogle Scholar
  • 16 Gallinella G, Venturoli S, Manaresi E. et al. B19 virus genome diversity: epidemiological and clinical correlations. J Clin Virol 2003; 28: 1-13.
    CrossrefPubMedGoogle Scholar
  • 17 Nguyen QT, Wong S, Heegaard ED. et al. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002; 301: 374-80.
    CrossrefPubMedGoogle Scholar
  • 18 Schneider B, Reber U, Tolba R. et al. Prevalence of human parvovirus genotype 1 and genotype 2 DNA in livers and bone marrows of adults. Annual Meeting of GfV – Joint Meeting with SIV, March 17-20, Tübingen, Germany..
    PubMedGoogle Scholar
  • 19 Eis-Hübinger AM, Sasowski U, Brackmann HH. et al. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. Thromb Haemost 1996; 76: 1120.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Hemauer A, von Poblotzki A, Gigler A. et al. Sequence variability among different parvovirus B19 isolates. J Gen Virol 1996; 77: 1781-5.
    CrossrefPubMedGoogle Scholar
  • 21 Shade RO, Blundell MC, Cotmore SF. et al. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986; 58: 921-36.
    PubMedGoogle Scholar
  • 22 Saldanha J, Lelie N, Yu MW. et al. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002; 82: 24-31.
    CrossrefPubMedGoogle Scholar
  • 23 Wong S, Young NS, Brown KE. Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associat-ed aplastic anemia. J Infect Dis 2003; 187: 1581-6.
    CrossrefPubMedGoogle Scholar
  • 24 Söderlund M, von Essen R, Haapasaari J. et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349: 1063-5.
    CrossrefPubMedGoogle Scholar
  • 25 Cassinotti P, Burtonboy G, Fopp M. et al. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997; 53: 229-32.
    CrossrefPubMedGoogle Scholar
  • 26 Eis-Hübinger AM, Reber U, Abdul-Nour T. et al. Evidence for persistence of parvovirus B19 DNA in livers of adults. J Med Virol 2001; 65: 395-401.
    CrossrefPubMedGoogle Scholar
  • 27 Musiani M, Zerbini M, Gentilomi G. et al. Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis 1995; 172: 1360-3.
    CrossrefPubMedGoogle Scholar
  • 28 Ozawa K, Kurtzman G, Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986; 233: 883-6.
    CrossrefPubMedGoogle Scholar
  • 29 Srivastava A, Lu L. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J Virol 1988; 62: 3059-63.
    PubMedGoogle Scholar
  • 30 Munshi NC, Zhou S, Woody MJ. et al. Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J Virol 1993; 67: 562-6.
    PubMedGoogle Scholar
  • 31 Blümel J, Schmidt I, Willkommen H. et al. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42: 1011-8.
    CrossrefPubMedGoogle Scholar
  • 32 Yunoki M, Tsujikawa M, Urayama T. et al. Heat sensitivity of human parvovirus B19. Vox Sang 2003; 84: 164-9.
    CrossrefPubMedGoogle Scholar
  • 33 Aubin JT, Defer C, Vidaud M. et al. Largescale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang 2000; 78: 7-12.
    CrossrefPubMedGoogle Scholar
  • 34 Cohen BJ, Field AM, Gudnadottir S. et al. Blood donor screening for parvovirus B19. J Virol Methods 1990; 30: 233-8.
    PubMedGoogle Scholar
  • 35 Brown KE, Young NS, Alving BM. et al. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41: 130-5.
    CrossrefPubMedGoogle Scholar